RESUMEN
OBJECTIVE: To study the relationship between serum adiponectin and insulin resistance in women with polycystic ovary syndrome (PCOS). METHODS: Forty women with PCOS and twenty five healthy women were divided into PCOS obese group [body weight index (BMI) > or = 25kg/m(2)], PCOS non-obese group (BMI < 25 kg/m(2)) and control group. There are 19 cases in PCOS obese group and 21 cases in PCOS non-obese group, 9 cases in obese control group and 16 in non-obese control group. Serum adiponectin levels of the four groups were detected by enzyme linked immunosorbent assay (ELISA) method, insulin by electrochemiluminescence immunoassay method, blood sugar by glucose oxidation enzyme method, tumor necrosis factor-alpha (TNF-alpha) by radioimmunoassay. Insulin sensitivity index (ISI) was calculated. RESULTS: (1) Serum adiponectin levels of PCOS obese group was (1.6 +/- 0.5) mg/L, of PCOS non-obese group was (3.0 +/- 0.6) mg/L. Their values were lower than obese control group (3.2 +/- 0.3) mg/L, and non-obese control group (4.9 +/- 0.5) mg/L (P < 0.05). (2) Fasting insulin levels of PCOS obese group was (17 +/- 6) mU/L, PCOS non-obese group was (14 +/- 6) mU/L. They were higher than obese control group (10 +/- 3) mU/L, and non-obese control group (7 +/- 3) mU/L (P < 0.05). (3) Fasting blood sugar level was (5.2 +/- 0.7) mmol/L in PCOS obese group, in PCOS non-obese group was (5.1 +/- 0.6) mmol/L, in obese control group was (5.4 +/- 0.5) mmol/L, and non-obese control group (4.8 +/- 0.6) mmol/L, without marked difference among four groups. (4) TNF-alpha levels of PCOS obese group was (1.32 +/- 0.14) microg/L, of PCOS non-obese group was (1.02 +/- 0.12) microg/L. They were higher than obese control group (0.93 +/- 0.15) microg/L, and non-obese control group (0.63 +/- 0.18) microg/L (P < 0.05). (5) ISI of PCOS obese group was -4.5 +/- 0.3, PCOS non-obese group was -4.1 +/- 0.4. Their values were lower than obese control group -3.6 +/- 0.3, and non-obese control group (-3.1 +/- 0.4) (P < 0.05). Serum adiponectin levels of the women with PCOS were correlated negatively with BMI (r = -0.56, P < 0.05), and correlated positively with ISI (r = 0.49, P < 0.05). CONCLUSION: Serum adiponectin levels of women with PCOS is decreased compared with healthy women, particularly in obese women with PCOS. The decrease is correlated with ISI.
Asunto(s)
Adiponectina/sangre , Resistencia a la Insulina , Obesidad/sangre , Síndrome del Ovario Poliquístico/sangre , Adulto , Glucemia/análisis , Índice de Masa Corporal , Ensayo de Inmunoadsorción Enzimática , Femenino , Prueba de Tolerancia a la Glucosa , Humanos , Insulina/sangre , Obesidad/fisiopatología , Síndrome del Ovario Poliquístico/fisiopatología , Factor de Necrosis Tumoral alfa/sangreRESUMEN
OBJECTIVE: To study the expression of glucose transporter-1 (GLUT1) and its correlation with basic fibroblast growth factor (bFGF) and proliferating cell nuclear antigen (PCNA) in epithelial ovarian neoplasm. METHODS: Streptavidin-peroxidase complex technique was used to examine the expression of GLUT1, bFGF and PCNA protein in six cases of normal ovarian tissue, 20 cases of benign epithelial tumors, seven cases of borderline tumor and 44 cases of epithelial ovarian carcinoma. RESULTS: In normal ovary and benign ovarian tumor, GLUT1 was not detected, but in borderline ovarian tumor and cancer, the positive expression ratio of GLUT1 was 6/7 and 91% (40/44), respectively. The intensity of GLUT1 in ovarian epithelial neoplasm was significantly higher than in borderline tumors. The staining intensity of GLUT1 was significantly correlated with the histological grade of the tumor (r(S) = 0.499, P = 0.001), and was positively correlated with the clinical stage, cancer invasion and lymph node metastasis. GLUT1 staining was intense in cytoplasmic membrane, and was stronger in areas far away from blood vessels and near the necrotic center. GLUT(1) expression level did not show any association with histology type (P = 0.513). bFGF positive rate in tumor was 57% (25/44). The staining intensity of GLUT1 was significantly higher in bFGF positive group than in bFGF negative group (P < 0.01). The mean score of PCNA was significantly higher in cancer tissues with strong GLUT1 staining(+++) than that with moderate(++) and low(+) GLUT1 staining (P < 0.05). And the score of PCNA was also significantly higher in bFGF positive group than in bFGF negative group (P < 0.01). CONCLUSIONS: (1) The expression of GLUT1 may be closely related to malignant transformation of ovarian epithelial tumors. It is also correlated with clinical stage, cancer invasion and lymph node metastasis, and may be a useful predictor of poor prognosis. (2) bFGF could enhance the expression of GLUT1. Both of them play important roles in the carcinogenesis and progression of ovarian epithelial carcinoma.